Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir

Clinical Infectious Diseases

Volumn 38, Issue 7, 2004, Pages 1017-1023

  Martínez, Esteban ^a,d   Domingo, Pere ^b   Galindo, María J ^c   Milinkovic, Ana ^a   Arroyo, Juan A ^b   Baldoví, Francisco ^c   Larrousse, María ^a   León, Agathe ^a   De Lazzari, Elisa ^a   Gatell, José M ^a  

^a INST D INVESTIGACIONS B   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL; ZIDOVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADULT; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL; CHEMICALLY INDUCED DISORDER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS; METABOLISM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHOLESTEROL; CHOLESTEROL, HDL; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; METABOLIC DISEASES; PYRIMIDINONES; RISK FACTORS; RITONAVIR; TRIGLYCERIDES;

EID: 11144357725     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382531     Document Type: Article

References (25)

1. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. M98-863 Study Team. N Engl J Med 2002; 346:2039-46.
2. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type I - infected protcase inhibitor-experienced patients. J Infect Dis 2002; 185:599-607.
3. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther 2002; 7:165-74.
4. Manfredi R, Chiodo F. Management of dyslipidaemia in patients with HIV disease. Clin Microbiol Infect 2000; 6:579-84.
5. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001; 357:592-8.
6. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20:1183-97.
7. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-23.
8. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
9. Badiou S, de Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J. Decrease in LDL size in HIV-positive adults before and after lopinavir/ritonavir-containing regimen: an index of atherogenicity? Atherosclerosis 2003; 168:107-13.
10. Lee GA, Seneviratne T, Noor MA, et al. Metabolic effects of lopinavir/ritonavir in healthy HIV-seronegative men [abstract 748]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Alexandria, VA: Foundation for Retrovirology and Human Health, 2003.
11. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy: results from the DAD study. DAD Study Group. AIDS 2003; 17:1179-93.
12. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO. Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 2003; 17:189-94.
13. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000; 14:51-7.
14. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. BEST Study Team. AIDS 1003; 17:831-40.
15. Cooper CL, van Heeswijk RPG, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003; 36:1585-92.
16. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir-containing regimens. J Acquir Immune Defic Syndr 2003; 33:594-600.
17. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS 2003; 17:443-5.
18. Tseng A, Loutfy M, Phillips E, Walker S, Rachlis A, Walmsley S. The relationship between lipid elevations and lopinavir concentrations in HIV-infected patients on lopinavir-ritonavir - containing salvage regimens [abstract H-1916]. In: Program and abstracts of the 42th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2002.
19. Calboreanu A, Dimet I, Treluyer JM, et al. Relation between lopinavir plasma blood concentrations and hypertriglyceridemia in naive and protease inhibitors - experienced patients [abstract 526]. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. Washington, DC: American Society for Microbiology, 2003.
20. Boffito M, Back DI, Hoggard PG, et al. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. AIDS 2003; 17:1107-8.
21. Fauvel I, Bonnet E, Ruidavets JB, et al. An interaction between apoC-III variants and protease inhibitors contributes to high triglycerides/low HDL levels in treated HIV patients. AIDS 2001; 15:2397-406.
22. Behrens G, Schmidt HH, Stoll M, Schmidt RE. ApoE genotype and protease inhibitor-associated hyperlipidemia. Lancet 1999; 354:76.
23. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998; 352:1031-2.
24. Powderly WG. Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 2002; 29:S28-40.
25. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31:257-75.